Seelos Therapeutics Inc (SEEL)

[DavenCT]

As Pascoe said, "“We are obviously disappointed with these results,” said Richard Pascoe, Chief Executive Officer of Apricus. “As a consequence of these results, we will discontinue all development of fispemifene in symptomatic secondary hypogonadism, and focus our resources on our other homegrown pipeline assets. Specifically, we will focus on growing ex-U.S. Vitaros® revenues, seeking U.S. Vitaros approval in 2017, and advancing RayVa™ with a Phase 2 clinical development program. We believe that focusing on these higher return assets, along with streamlining the organization and reducing our operating expenses, is in the best interest of shareholders.”

Looks like a couple of the recently hired folks will be giving up their parking passes. Maybe, just maybe, 'in the best interests of the organization,' Pascoe will reduce his operating expense! It would be nice to hear him say, "I'll work for $50,000 a year until RayVa is commercialized." But I don't think his ego will let him do that.